Regeneron Pharmaceuticals Inc. (REGN)

298.37
0.17 0.06
NASDAQ : Health Technology
Prev Close 298.20
Open 299.19
Day Low/High 295.78 / 299.69
52 Wk Low/High 287.66 / 442.00
Volume 492.34K
Avg Volume 898.20K
Exchange NASDAQ
Shares Outstanding 107.73M
Market Cap 32.08B
EPS 22.60
P/E Ratio 13.85
Div & Yield N.A. (N.A)
Cramer: Biogen's Horseman May Have Fallen Off, I Like Others More

Cramer: Biogen's Horseman May Have Fallen Off, I Like Others More

TheStreet's Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

When Leader Goes Down, Whole Sector Feels It

Biogen's weak numbers leave biotechs ailing.

Are Any New FANGs Baring Their Teeth?

The fearsome foursome have been reborn.

Cramer: Own Starbucks Over Dunkin, PayPal IPO Is a Buy Right Now

Cramer: Own Starbucks Over Dunkin, PayPal IPO Is a Buy Right Now

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

iShares Nasdaq Biotech ETF is Just What the Doctor Ordered for Your Portfolio

Technical factors point to a looming breakout for IBB.

Regeneron Reaches a Great Entry Point

This could be an opportune price to buy REGN, as it allows you to take a position fairly close to well-defined support.

Biotech Moves Are Anything But Crazy

New companies are coming up with major drugs.

A Stellar Day. But Why?

Bulls have the upper hand again.

Playing Biotechs with the House's Money

Playing Biotechs with the House's Money

Here's how to lock in gains on risky small-cap biotechnology stocks.

Cramer: Intel Had to Be Aggressive With Altera, Don't Sell Amgen

Cramer: Intel Had to Be Aggressive With Altera, Don't Sell Amgen

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

What's Wrong With Betting on One Stock?

'Single-stock risk' is all the rage these days.

Why I'm Looking at Biotechs, Not Airlines

Cutthroat competition is good for customers, but not shareholders.

3 Biotechs That Are Worth Buying

Many of these stocks are off to the races.

The Second-Strongest Stock Market Sector Doesn't Jibe With the Strongest

You could throw darts at financials and health care and win. 

Where to Invest to Shelter From the Market Rotation Crossfire

Some companies are so strong that they buck the rotation.

Cramer: I Like Receptos and Radius, as Well as the Four Horsemen

Cramer: I Like Receptos and Radius, as Well as the Four Horsemen

Jim Cramer answers viewers' stock questions from the floor of the New York Stock Exchange.

Janet Yellen, Stock Market Commentator?

It's not the Fed chief's place.

Here's What's Driving Biotech

And it's not the favorable macroeconomic climate.

I'm Going to Keep Riding These Horses

Biogen miss no reason to abandon big 4 of Big Pharma.

Mylan Deal the Rx for Drug Stocks

Even the second-tier biotechs are taking off.

Biotech Investors: Buy In or Get Out

No more hand-holding on these names.

Portfolio Managers Shop for Growth

Combined Heinz-Kraft heads a long second-quarter list.

Answering Your Tweets

An answer to those asking me what's worth buying.

Biotech, Chips Stand Their Ground

You can't help but feel better about both groups.

Biotechs Need to Rest

If there is no catalyst, I'd join those who sell on a bounce.

Backing Away From Biotechs

This sector could see some real damage.

The 7 Pillars of Healthcare Strength

Here are healthcare stocks of all shares and sizes with strong charts.

Biotech Stocks at a Crossroad

Own them, or take something off the table?

I'm Making a Don't-Buy Call on Biotech

I really like the stocks. But I also like making money on stocks.